Revium Rx growth metrics data for the quarter ended Jun 2026. These growth metrics cover 2 quarters of results from Dec 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Dec2025 | Jun2026 |
|---|---|---|
| Growth Ratios | ||
| Assets Growth (1y) | -59.07% | |
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | -48.65% | |
| EBIT Growth (1y) | 21.96% | |
| EBT Growth (1y) | 21.96% | |
| EPS (Basic) Growth (1y) | 21.96% | |
| EPS (Diluted) Growth (1y) | 21.96% | |
| Net Income Growth (1y) | 21.96% | |
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | 21.96% | |
| Operating Income Growth (1y)Op. Inc Growth (1y) | 21.96% | |
| Profit After Tax Growth (1y)PAT Growth (1y) | 28.01% | |
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | 11.11% | |
| Share-based Compensation Growth (1y)Stock Comp. Growth (1y) | -13.91% | 2,192.21% |
| Total Debt Growth (1y) | -99.54% |